Mignon L Loh

List of Publications by Year in Descending Order

368 papers	19,875 citations	76 h-index	136 g-index
398 ext. papers	23,966 ext. citations	6.3 avg, IF	6.14 L-index

#	Paper	IF	Citations
368	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.. *Journal of Clinical Oncology*, **2022**, JCO2101693	2.2	3
367	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.. *Nature Genetics*, **2022**, 54, 170-179	36.3	0
366	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.. *Cancer*, **2022**,	6.4	2
365	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.. *Journal of Clinical Oncology*, **2022** , JCO2102678	2.2	3
364	International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. *Clinical Cancer Research*, **2021**, 27, 158-168	12.9	7
363	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. *Blood*, **2021**, 138, 2382-2382	2.2	
362	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2021**, 138, 3487-3487	2.2	
361	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 3476-3476	2.2	
360	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. *Blood*, **2021**, 138, 363-363	2.2	1
359	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 614-614	2.2	
358	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. *Blood*, **2021**, 138, 2304-2304	2.2	3
357	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. *Blood*, **2021**, 138, 3679-3679	2.2	1
356	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. *Blood*, **2021**, 138, 3398-3398	2.2	1
355	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. *Blood*, **2021**, 138, 211-211	2.2	1
354	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. *Journal of the National Cancer Institute*, **2021**, 113, 933-937	9.7	5
353	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	6
352	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. *Leukemia*, **2021**, 35, 3272-3277	10.7	12

351	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 833-842	27.4	54
350	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 794-802	6.1	4
349	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. *Journal of Clinical Oncology*, **2021**, 39, 1437-1447	2.2	10
348	Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. *Journal of Clinical Oncology*, **2021**, 39, 1540-1552	2.2	4
347	Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. *Leukemia*, **2021**,	10.7	1
346	Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. *Blood*, **2021**,	2.2	5
345	Enhancer Hijacking Drives Oncogenic Expression in Lineage-Ambiguous Stem Cell Leukemia. *Cancer Discovery*, **2021**, 11, 2846-2867	24.4	12
344	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. *Blood Advances*, **2021**, 5, 2890-2900	7.8	1
343	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. *Blood* , **2021**, 137, 1550-1552	2.2	2
342	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. *Blood* , **2021**, 137, 364-373	2.2	7
341	SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. *Blood*, **2021**, 137, 1835-1838	2.2	1
340	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. *Blood*, **2021**, 137, 168-177	2.2	13
339	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. *Journal of the National Cancer Institute*, **2021**, 113, 408-417	9.7	7
338	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. *Blood Advances*, **2021**, 5, 504-512	7.8	9
337	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. *Lancet Haematology,the*, **2021**, 8, e55-e66	14.6	14
336	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. *Leukemia*, **2021**, 35, 1279-1290	10.7	6
335	The T681I mutation is highly resistant to imatinib and dasatinib and detectable in clinical samples prior to treatment. *Haematologica*, **2021**, 106, 2242-2245	6.6	2
334	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. *Cancer Discovery*, **2021**, 11, 1424-1439	24.4	4

333	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. *Pediatric Blood and Cancer* , **2021**, 68, e28929	3	0
332	Aurora A kinase as a target for therapy in rearranged acute lymphoblastic leukemia. *Haematologica*, **2021**, 106, 2990-2994	6.6	1
331	Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. *JAMA Oncology*, **2021**, 7, 1521-1528	13.4	2
330	Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. *Blood Advances*, **2021**, 5, 3587-3591	7.8	0
329	Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. *Blood Advances*, **2021**, 5, 4783-4793	7.8	1
328	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. *Journal of Clinical Investigation*, **2021**,	15.9	6
327	A simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. *Blood Advances*, **2021**,	7.8	1
326	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. *Pediatric Blood and Cancer*, **2020**, 67, e28409	3	74
325	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. *Molecular Cancer Research* , **2020**, 18, 1153-1165	6.6	4
324	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. *Journal of Clinical Oncology*, **2020**, 38, 2628-2638	2.2	9
323	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. *Journal of Clinical Oncology*, **2020**, 38, 3062-3070	2.2	22
322	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). *Blood*, **2020**, 136, 44-45	2.2	1
321	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). *Blood*, **2020**, 136, 47-47	2.2	
320	Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia. *Blood*, **2020**, 136, 19-20	2.2	
319	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. *Blood*, **2020**, 136, 39-40	2.2	
318	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. *Blood*, **2020**, 136, 37-38	2.2	0
317	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. *Blood*, **2020**, 136, 38-39	2.2	
316	Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study. *Blood*, **2020**, 136, 16-17	2.2	1

315	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. *Blood*, **2020**, 136, 20-21	2.2	3
314	Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. *Haematologica*, **2020**, Online ahead of print,	6.6	3
313	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. *Journal of Clinical Oncology*, **2020**, 38, 10509-10509	2.2	1
312	Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. *Cancer*, **2020**, 126, 593-601	6.4	18
311	Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies. *American Journal of Medical Genetics, Part A*, **2020**, 182, 866-876	2.5	24
310	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. *Journal of Clinical Oncology*, **2020**, 38, 602-612	2.2	52
309	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. *Cancer Research*, **2020**, 80, 5189-5202	10.1	4
308	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. *Nature Cancer*, **2020**, 1, 1113-1127	15.4	7
307	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 3282-3293	2.2	51
306	Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. *Leukemia*, **2020**, 34, 662-666	10.7	14
305	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2020**, 38, 1897-1905	2.2	49
304	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. *Leukemia and Lymphoma*, **2019**, 60, 1740-1748	1.9	18
303	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. *Haematologica*, **2019**, 104, e517-e520	6.6	7
302	Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. *Cancer Science*, **2019**, 110, 1931-1946	6.9	15
301	Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. *Cancer Research*, **2019**, 79, 2339-2351	10.1	35
300	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. *Pediatric Blood and Cancer*, **2019**, 66, e27681	3	3
299	Genomic subtyping and therapeutic targeting of acute erythroleukemia. *Nature Genetics*, **2019**, 51, 694-704	30.3	54
298	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. *Journal of Clinical Oncology*, **2019**, 37, 780-789	2.2	33

297	Case report: Impact of BITE on CAR-T cell expansion. *Advances in Cell and Gene Therapy*, **2019**, 2, e50	1.2	4
296	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. *Leukemia*, **2019**, 33, 181-190	10.7	28
295	Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. *British Journal of Haematology*, **2019**, 185, 169-174	4.5	6
294	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. *Cancer Genetics*, **2019**, 238, 62-68	2.3	21
293	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. *Blood*, **2019**, 134, 1227-1237	2.2	23
292	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. *Pediatric Blood and Cancer*, **2019**, 66, e27948	3	9
291	Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. *Pediatric Blood and Cancer*, **2019**, 66, e27905	3	5
290	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. *PLoS ONE*, **2019**, 14, e0221288	3.7	12
289	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. *Blood*, **2019**, 134, 652-652	2.2	6
288	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. *Blood*, **2019**, 134, 741-741	2.2	28
287	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. *Blood*, **2019**, 134, 2649-2649	2.2	10
286	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. *Blood*, **2019**, 134, 1293-1293	2.2	4
285	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. *Blood*, **2019**, 134, LBA-1-LBA-1	2.2	34
284	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study.. *Journal of Clinical Oncology*, **2019**, 37, 10008-10008	2.2	15
283	Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia. *Blood*, **2019**, 134, 650-650	2.2	
282	RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 3947-3947	2.2	0
281	DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation. *Blood*, **2019**, 134, 1693-1693	2.2	
280	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli-Derived Asparaginases. *Blood*, **2019**, 134, 2586-2586	2.2	

279	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. *Nature Communications*, **2019**, 10, 5348	17.4	29
278	Downregulating Notch counteracts Kras-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. *Leukemia*, **2019**, 33, 671-685	10.7	6
277	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. *Haematologica*, **2019**, 104, 986-992	6.6	12
276	Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. *Cancer Discovery*, **2019**, 9, 436-451	24.4	31
275	Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. *Journal of Medicinal Chemistry*, **2019**, 62, 1125-1137	8.3	32
274	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nature Genetics*, **2019**, 51, 296-307	36.3	189
273	Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics. *Blood*, **2019**, 133, 724-729	2.2	29
272	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *Leukemia*, **2019**, 33, 884-892	10.7	119
271	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). *Leukemia*, **2018**, 32, 1370-1379	10.7	25
270	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. *Leukemia*, **2018**, 32, 2126-2137	10.7	38
269	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. *Cancer Cell*, **2018**, 33, 937-948.e8	24.3	98
268	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. *Future Oncology*, **2018**, 14, 2115-2129	3.6	27
267	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. *Pediatric Blood and Cancer*, **2018**, 65, e27062	3	31
266	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. *Nature*, **2018**, 553, 511-514	50.4	67
265	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. *Cancer*, **2018**, 124, 1150-1159	6.4	18
264	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. *Pediatric Blood and Cancer*, **2018**, 65, e26928	3	19
263	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. *Blood*, **2018**, 131, 1350-1359	2.2	108
262	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. *Blood*, **2018**, 131, 995-999	2.2	112

261	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. *Pediatric Blood and Cancer*, **2018**, 65, e27034	3	17
260	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2018**, 65, e26873	3	37
259	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. *Blood*, **2018**, 132, 815-824	2.2	58
258	Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. *Stem Cell Research*, **2018**, 31, 157-160	1.6	6
257	Using genomics to define pediatric blood cancers and inform practice. *Hematology American Society of Hematology Education Program*, **2018**, 2018, 286-300	3.1	4
256	A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. *Blood*, **2018**, 132, 555-555	2.2	23
255	Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331. *Blood*, **2018**, 132, 1382-1382	2.2	5
254	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). *Blood*, **2018**, 132, 1000-1000	2.2	1
253	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. *Blood*, **2018**, 132, 35-35	2.2	6
252	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. *Blood*, **2018**, 132, 1405-1405	2.2	3
251	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. *Blood*, **2018**, 132, 261-261	2.2	2
250	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 565-565	2.2	1
249	Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 4026-4026	2.2	1
248	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. *Blood*, **2018**, 132, 659-659	2.2	
247	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. *Cancer*, **2018**, 124, 571-579	6.4	15
246	Severe pegaspargase hypersensitivity reaction rates (grade ⍰) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. *Leukemia and Lymphoma*, **2018**, 59, 1624-1633	1.9	24
245	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. *Journal of Clinical Oncology*, **2018**, 36, 2306-2314	2.2	119
244	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. *Journal of Clinical Oncology*, **2018**, 36, 591-599	2.2	85

243	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. *Journal of Experimental Medicine*, **2018**, 215, 3094-3114	16.6	26
242	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. *Journal of Clinical Oncology*, **2018**, 36, 2926-2934	2.2	95
241	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. *JCI Insight*, **2018**, 3,	9.9	37
240	The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature*, **2018**, 562, 373-379	50.4	140
239	Characterization of PAX5-driven Subtypes in B-progenitor Acute Lymphoblastic Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, S183	2	2
238	Dysregulated transcriptional networks in and -rearranged T-ALL. *Biomarker Research*, **2018**, 6, 27	8	7
237	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. *Blood Advances*, **2018**, 2, 529-533	7.8	21
236	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. *SLAS Discovery*, **2018**, 23, 732-741	3.4	4
235	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. *Blood*, **2017**, 129, 177-187	2.2	101
234	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. *Blood*, **2017**, 129, e26-e37	2.2	107
233	Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. *Blood*, **2017**, 129, 3000-3008	2.2	33
232	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. *Blood*, **2017**, 129, 3352-3361	2.2	168
231	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. *Blood*, **2017**, 130, 397-407	2.2	88
230	Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. *Clinical Cancer Research*, **2017**, 23, 5329-5338	12.9	16
229	Philadelphia chromosome-like acute lymphoblastic leukemia. *Blood*, **2017**, 130, 2064-2072	2.2	125
228	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 2700-2707	2.2	20
227	Reply to I.J. Cohen. *Journal of Clinical Oncology*, **2017**, 35, 3989-3991	2.2	1
226	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 2527-2534	2.2	43

225	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nature Genetics*, **2017**, 49, 1211-1218	36.3	430
224	Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. *British Journal of Haematology*, **2017**, 179, 843-846	4.5	2
223	Somatic and Germline Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. *Clinical Cancer Research*, **2017**, 23, 1852-1861	12.9	20
222	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). *Leukemia*, **2017**,	10.7	1
221	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. *Nature Communications*, **2017**, 8, 2127	17.4	47
220	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). *Blood*, **2017**, 130, 98-98	2.2	17
219	Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. *Blood Advances*, **2017**, 1, 1657-1671	7.8	56
218	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. *Blood*, **2017**, 130, 883-883	2.2	1
217	Characterization of leukemias with ETV6-ABL1 fusion. *Haematologica*, **2016**, 101, 1082-93	6.6	49
216	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 11306-11311	11.5	117
215	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. *Nature Communications*, **2016**, 7, 13331	17.4	128
214	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nature Genetics*, **2016**, 48, 1481-1489	36.3	145
213	Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. *Nature*, **2016**, 539, 304-308	50.4	154
212	Germline mutations are not associated with Noonan syndrome. *Journal of Medical Genetics*, **2016**, 53, 728	5.8	3
211	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. *International Journal of Cancer*, **2016**, 138, 332-9	7.5	44
210	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. *Nature Communications*, **2016**, 7, 10647	17.4	10
209	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. *Cancer Cell*, **2016**, 29, 186-200	24.3	92
208	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. *Blood*, **2016**, 128, 1085-1085	2.2	1

207	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. *Blood*, **2016**, 128, 1086-1086	2.2	2
206	BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 280-280	2.2	5
205	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. *Blood*, **2016**, 128, 39-39	2.2	2
204	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. *Blood*, **2016**, 128, 3965-3965	2.2	3
203	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. *Blood*, **2016**, 128, 451-451	2.2	3
202	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. *Blood*, **2016**, 128, 454-454	2.2	3
201	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 604-604	2.2	1
200	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). *Blood*, **2016**, 128, 758-758	2.2	1
199	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. *Blood*, **2016**, 128, 4083-4083	2.2	
198	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 2906-2906	2.2	
197	Improved Diagnosis of Intrachromosomal Amplification of Chromosome 21 (iAMP21) By Copy Number Profiling. *Blood*, **2016**, 128, 1733-1733	2.2	
196	RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia. *Blood*, **2016**, 128, 2699-2699	2.2	
195	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. *Blood*, **2016**, 128, 455-455	2.2	0
194	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. *Blood*, **2016**, 128, 1739-1739	2.2	
193	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. *Blood*, **2016**, 128, 1729-1729	2.2	
192	Ph-like acute lymphoblastic leukemia. *Hematology American Society of Hematology Education Program*, **2016**, 2016, 561-566	3.1	43
191	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. *Nature Communications*, **2016**, 7, 10635	17.4	37
190	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. *Journal of Clinical Oncology*, **2016**, 34, 2380-8	2.2	219

189	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2016**, 34, 2133-40	2.2	57
188	Pediatric MDS: GATA screen the germline. *Blood*, **2016**, 127, 1377-8	2.2	2
187	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. *Blood*, **2016**, 127, 558-64	2.2	47
186	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. *Cancer Cell*, **2015**, 27, 409-25	24.3	81
185	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. *Nature Communications*, **2015**, 6, 7553	17.4	51
184	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. *Blood*, **2015**, 125, 1759-67	2.2	147
183	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2015**, 313, 815-23	27.4	179
182	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. *Nature*, **2015**, 521, 357-61	50.4	90
181	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nature Communications*, **2015**, 6, 6604	17.4	215
180	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. *Lancet Oncology, The*, **2015**, 16, 1659-66	21.7	123
179	The genomic landscape of juvenile myelomonocytic leukemia. *Nature Genetics*, **2015**, 47, 1326-1333	36.3	166
178	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. *Cancer Genetics*, **2015**, 208, 1-18	2.3	26
177	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 414-8	3	28
176	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. *Blood*, **2015**, 125, 680-6	2.2	84
175	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. *Blood*, **2015**, 126, 964-71	2.2	217
174	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. *Haematologica*, **2015**, 100, 17-22	6.6	34
173	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. *Cancer*, **2015**, 121, 3577-90	6.4	41
172	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 629-36	3	34

171	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). *Pediatric Blood and Cancer*, **2015**, 62, 1717-24	3	72
170	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. *Pediatric Blood and Cancer*, **2015**, 62, 1176-83	3	65
169	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. *Blood* , **2015**, 125, 516-24	2.2	56
168	Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. *Molecular Cancer Therapeutics*, **2015**, 14, 364-74	6.1	41
167	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131. *Blood*, **2015**, 126, 1303-1303	2.2	6
166	Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 1423-1423	2.2	1
165	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. *Blood*, **2015**, 126, 2502-2502	2.2	5
164	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 3765-3765	2.2	3
163	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. *Blood*, **2015**, 126, 3792-3792	2.2	8
162	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 691-691	2.2	3
161	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 693-693	2.2	1
160	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *Blood*, **2015**, 126, 694-694	2.2	1
159	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. *Blood*, **2015**, 126, 794-794	2.2	11
158	Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 798-798	2.2	2
157	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). *Blood*, **2015**, 126, 807-807	2.2	4
156	CblY371H Transgene Combined with Hematopoietic Deletion of the Endogenous c-Cbl Gene Results in GM-CSF Hypersensitivity and Leukocytosis. *Blood*, **2015**, 126, 3672-3672	2.2	
155	Characterization of Leukemias with ETV6-ABL1 Fusion. *Blood*, **2015**, 126, 84-84	2.2	1
154	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 695-695	2.2	

153	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 556-556	2.2	
152	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. *Journal of Clinical Oncology*, **2014**, 32, 3874-82	2.2	66
151	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science*, **2014**, 346, 1373-7	33.3	484
150	Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. *Cancer Discovery*, **2014**, 4, 1074-87	24.4	146
149	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *New England Journal of Medicine*, **2014**, 371, 1005-15	59.2	885
148	Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. *Clinical Cancer Research*, **2014**, 20, 4540-8	12.9	110
147	Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. *Blood*, **2014**, 124, 2487-97	2.2	76
146	PI3K p110□uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. *Blood*, **2014**, 123, 2838-42	2.2	31
145	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. *Blood*, **2014**, 123, 1426-7	2.2	11
144	A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype. *Human Heredity*, **2014**, 78, 104-16	1.1	13
143	Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. *Human Molecular Genetics*, **2014**, 23, 4315-27	5.6	95
142	Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. *Frontiers in Pediatrics*, **2014**, 2, 25	3.4	36
141	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children□ Oncology Group (COG) Study AALL0434. *Blood*, **2014**, 124, 1-1	2.2	80
140	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children□ Oncology Group (COG) Study AALL0434. *Blood*, **2014**, 124, 3648-3648	2.2	5
139	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. *Blood*, **2014**, 124, 367-367	2.2	1
138	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 786-786	2.2	2
137	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children□ Oncology Group (COG) Study AALL0331. *Blood*, **2014**, 124, 793-793	2.2	13
136	Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. *Blood*, **2014**, 124, 410-410	2.2	

135	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 612-612	2.2	
134	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. *Blood*, **2014**, 124, 63-63	2.2	
133	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 3570-3570	2.2	
132	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 128-128	2.2	
131	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 284-284	2.2	
130	Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers. *Blood*, **2014**, 124, 2207-2207	2.2	
129	Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). *Journal of Medicinal Chemistry*, **2013**, 56, 7212-21	8.3	48
128	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. *Blood*, **2013**, 121, 4925-9	2.2	80
127	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. *Blood*, **2013**, 121, 485-8	2.2	136
126	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. *Pediatric Blood and Cancer*, **2013**, 60, 957-63	3	121
125	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nature Genetics*, **2013**, 45, 1494-8	36.3	205
124	Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. *Molecular Cancer Therapeutics*, **2013**, 12, 1738-48	6.1	33
123	Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. *Science Signaling*, **2013**, 6, ra21	8.8	31
122	Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. *Cancer Research*, **2013**, 73, 2540-50	10.1	23
121	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. *Journal of the National Cancer Institute*, **2013**, 105, 733-42	9.7	167
120	Genetic predispositions to childhood leukemia. *Therapeutic Advances in Hematology*, **2013**, 4, 270-90	5.7	51
119	Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. *Journal of Clinical Oncology*, **2013**, 31, 3397-402	2.2	99
118	The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 242-52	36.3	474

117	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. *Blood*, **2013**, 121, 1814-8	2.2	82
116	Genome-wide study of methotrexate clearance replicates SLCO1B1. *Blood*, **2013**, 121, 898-904	2.2	137
115	Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome. *Pediatric Blood and Cancer*, **2013**, 60, 754-60	3	19
114	GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure. *Blood*, **2013**, 122, 1520-1520	2.2	3
113	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 232-232	2.2	6
112	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. *Blood*, **2013**, 122, 2550-2550	2.2	1
111	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 2672-2672	2.2	5
110	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. *Blood*, **2013**, 122, 3736-3736	2.2	1
109	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). *Blood*, **2013**, 122, 45-45	2.2	1
108	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 60-60	2.2	1
107	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 618-618	2.2	5
106	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. *Blood*, **2013**, 122, 824-824	2.2	3
105	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. *Blood*, **2013**, 122, 825-825	2.2	4
104	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (Ph-like or BCR-ABL1-Like) Signature For Therapeutic Targeting	2.2	45
103	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. *Blood*, **2013**, 122, 837-837	2.2	9
102	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. *ELife*, **2013**, 2, e00825	8.9	21
101	Genomic- and Transcriptomic Profiling Of Acute Lymphoblastic Leukemia With Dicentric Chromosomes. *Blood*, **2013**, 122, 234-234	2.2	1
100	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 3868-3868	2.2	

99	Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1526-1526	2.2	
98	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. *Blood*, **2013**, 122, 1341-1341	2.2	
97	Overexpression Of Leukemia Associated CblY371H Mutation In Transgenic Mice Causes Dosage Dependent Embryonic Lethality. *Blood*, **2013**, 122, 2515-2515	2.2	
96	Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. *Blood*, **2013**, 122, 2628-2628	2.2	
95	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **2012**, 119, 3512-22	2.2	181
94	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. *Blood*, **2012**, 120, 833-42	2.2	166
93	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. *Blood*, **2012**, 120, 3510-8	2.2	220
92	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*, **2012**, 22, 153-66	24.3	515
91	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature*, **2012**, 481, 157-63	50.4	1163
90	High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. *Science Translational Medicine*, **2012**, 4, 134ra63	17.5	175
89	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2012**, 30, 751-7	2.2	131
88	Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. *Clinical Cancer Research*, **2012**, 18, 2754-67	12.9	46
87	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. *Blood*, **2012**, 120, 137-137	2.2	4
86	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. *Blood*, **2012**, 120, 2466-2466	2.2	1
85	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. *Blood*, **2012**, 120, 2529-2529	2.2	1
84	Clinical Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD): A Distinct Clinical Entity Mimicking Juvenile Myelomonocytioc Leukemia (JMML) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2012**, 120, 1033-1033	2.2	
83	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. *Blood*, **2012**, 120, 1440-1440	2.2	
82	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 878-878	2.2	

81	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. *Blood*, **2012**, 120, 877-877	2.2	0
80	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 289-289	2.2	4
79	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. *Blood*, **2012**, 120, 2505-2505	2.2	
78	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2011**, 118, 3080-7	2.2	218
77	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. *Blood*, **2011**, 118, 2191-9	2.2	89
76	Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. *British Journal of Haematology*, **2011**, 152, 677-87	4.5	119
75	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. *Nature Genetics*, **2011**, 43, 237-41	36.3	201
74	Improving outcomes for high-risk ALL: translating new discoveries into clinical care. *Pediatric Blood and Cancer*, **2011**, 56, 984-93	3	51
73	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. *Blood*, **2011**, 118, 1440-1440	2.2	3
72	High-Throughput Screening by Flow Cytometry Identifies Reduced Expression of CD48 As a Universal Characteristic of T-ALL and a Suitable Target for Minimal Residual Disease (MRD) Detection. *Blood*, **2011**, 118, 2547-2547	2.2	2
71	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. *Blood*, **2011**, 118, 743-743	2.2	1
70	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). *Blood*, **2011**, 118, 249-249	2.2	
69	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. *Blood*, **2011**, 118, 739-739	2.2	1
68	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. *Blood*, **2011**, 118, 67-67	2.2	
67	Patient-Derived Induced Pluripotent Stem Cells Recapitulate Hematopoietic Abnormalities of Juvenile Myelomonocytic Leukemia. *Blood*, **2011**, 118, 637-637	2.2	
66	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. *Blood*, **2011**, 118, 68-68	2.2	
65	High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia. *Blood*, **2011**, 118, 2545-2545	2.2	
64	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. *Nature Genetics*, **2010**, 42, 794-800	36.3	257

63	Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 357-62	3.1	27
62	Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2010**, 28, 3816-23	2.2	79
61	Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. *Pediatric Blood and Cancer*, **2010**, 55, 421-9	3	80
60	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. *Blood*, **2010**, 116, 2752-2752	2.2	2
59	Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. *Blood*, **2010**, 116, 410-410	2.2	4
58	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. *Blood*, **2010**, 116, 411-411	2.2	3
57	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. *Blood*, **2010**, 116, 869-869	2.2	1
56	Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. *Blood*, **2010**, 116, 414-414	2.2	
55	Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/Ecatenin. *Blood*, **2010**, 116, 3264-3264	2.2	
54	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *Blood*, **2010**, 116, 8-8	2.2	
53	Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 3263-3263	2.2	
52	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 3251-3251	2.2	
51	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. *Blood*, **2010**, 116, 315-315	2.2	2
50	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Blood*, **2010**, 116, 865-865	2.2	1
49	JAK mutations in high-risk childhood acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 9414-8	11.5	446
48	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. *Pediatric Blood and Cancer*, **2009**, 52, 259-62	3	44
47	A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. *Blood*, **2009**, 113, 1075-85	2.2	43
46	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. *Blood*, **2009**, 114, 1859-63	2.2	212

45	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. *Blood*, **2009**, 114, 1580-1580	2.2	6
44	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. *Blood*, **2009**, 114, 310-310	2.2	1
43	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. *Blood*, **2009**, 114, 704-704	2.2	12
42	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. *Blood*, **2009**, 114, 85-85	2.2	4
41	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction: A Children's Oncology Group (COG) Study.. *Blood*, **2009**, 114, 9-9	2.2	14
40	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. *Blood*, **2009**, 114, 2598-2598	2.2	1
39	Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. *Cancer Cell*, **2008**, 14, 335-43	24.3	195
38	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. *Blood*, **2008**, 111, 1124-7	2.2	31
37	Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally. *Cancer Research*, **2008**, 68, 9935-44	10.1	20
36	JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I. *Pediatric Blood and Cancer*, **2008**, 51, 689-91	3	2
35	SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. *Genes Chromosomes and Cancer*, **2008**, 47, 253-9	5	33
34	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children Oncology Group (COG) Study.. *Blood*, **2008**, 112, 2256-2256	2.2	
33	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children Oncology Group Trials.. *Blood*, **2008**, 112, 1514-1514	2.2	
32	Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. *Journal of Clinical Oncology*, **2007**, 25, 813-9	2.2	147
31	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). *Blood*, **2007**, 109, 926-35	2.2	338
30	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. *Blood*, **2007**, 110, 120-120	2.2	2
29	A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.. *Blood*, **2007**, 110, 546-546	2.2	2
28	Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children Oncology Group.. *Blood*, **2007**, 110, 758-758	2.2	

27	Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.. *Blood*, **2007**, 110, 854-854	2.2	
26	Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.. *Blood*, **2007**, 110, 2657-2657	2.2	
25	A Rare Case of JAK2 V617F Positive Polycythemia Vera in a Child with Neurofibromatosis Type I.. *Blood*, **2007**, 110, 4661-4661	2.2	
24	Congenital leukemia cutis with subsequent development of leukemia. *Journal of the American Academy of Dermatology*, **2006**, 54, S22-7	4.5	35
23	Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. *Blood*, **2006**, 107, 4508-13	2.2	87
22	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. *Blood*, **2006**, 107, 2639-42	2.2	183
21	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. *Pediatric Blood and Cancer*, **2006**, 46, 579-85	3	91
20	Factors Influencing Survival after Relapse from Childhood ALL: A Children Oncology Group Study.. *Blood*, **2006**, 108, 1855-1855	2.2	3
19	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.. *Blood*, **2006**, 108, 2681-2681	2.2	1
18	Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. *Leukemia Research*, **2005**, 29, 459-62	2.7	49
17	Phamacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).. *Blood*, **2005**, 106, 1243-1243	2.2	2
16	Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children Oncology Group Study.. *Blood*, **2005**, 106, 2587-2587	2.2	16
15	Cytogenetics of Hispanics and Whites with Childhood Acute Lymphoblastic Leukemia in California.. *Blood*, **2005**, 106, 4536-4536	2.2	
14	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. *Cancer Research*, **2004**, 64, 8816-20	10.1	404
13	SHP-2 and myeloid malignancies. *Current Opinion in Hematology*, **2004**, 11, 44-50	3.3	84
12	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. *Blood*, **2004**, 103, 2325-31	2.2	358
11	PTPN11 Mutational Spectrum in Juvenile Myelomonocytic Leukemia and Noonan Syndrome.. *Blood*, **2004**, 104, 3417-3417	2.2	1
10	Functional Analysis of Leukemia-Associated PTPN11 Mutations in Primary Hematopoietic Cells.. *Blood*, **2004**, 104, 2423-2423	2.2	

9	Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. *Genes Chromosomes and Cancer*, **2003**, 37, 36-43	5	68
8	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. *Current Opinion in Hematology*, **2002**, 9, 345-52	3.3	56
7	Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 722-6	1.2	87
6	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. *Cancer Cell*, **2002**, 1, 75-87	24.3	895
5	Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia. *Cancer Genetics and Cytogenetics*, **2000** , 122, 79-82		10
4	Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. *Molecular Cell*, **2000**, 6, 693-704	17.6	266
3	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. *Nature Genetics*, **1999**, 23, 166-75	36.3	897
2	Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1. *Leukemia Research*, **1998**, 22, 461-4	2.7	12
1	Congenital fibrosarcoma of the upper extremity. *Plastic and Reconstructive Surgery*, **1998**, 102, 1158-62	2.7	24